GAITHERSBURG, Md., Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today announced it will report its third quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Tuesday, November 12, 2024. Details of the event and replay are as follows:

• Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
• Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
• To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.

Contacts:

Investors
Luis Sanay, CFA
240-268-2022
[email protected]

Media
Giovanna Chandler
202-709-5563
[email protected]

SOURCE Novavax, Inc.